Verruca vulgaris developing during cyclosporin therapy for psoriasis vulgaris.
Several kinds of side effects have recently been reported with cyclosporin (CsA) therapy. We describe two patients with psoriasis vulgaris who developed verrucae vulgaris during systemic CsA therapy. In one case, a verrucous nodule appeared on the scalp and grew rapidly in a 54-year-old male with psoriasis vulgaris 29 months after starting CsA therapy. The total dose of CsA was 87.5 g, and average dose of CsA was 2 mg/kg/day. In the other case, multiple verrucae vulgaris developed on the scalp, face, knee, and inguinal region in a 54-year-old male. He had been given CsA for 10 months, the total dose was 45.5 g, and the average dose was 3 mg/kg/day. He also had Sjögren's syndrome. Most of the verrucae vulgaris lesions spontaneously disappeared after stopping the CsA.
Irimajiri
J
J
Department of Dermatology, Tokyo Medical and Dental University School of Medicine, Japan.
Yamamoto
T
T
Kimura
K
K
Yokozeki
H
H
Nishioka
K
K
D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005148:Facial Dermatoses / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007868:Leg Dermatoses / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D012536:Scalp Dermatoses / Q000139:chemically induced; D012859:Sjogren's Syndrome / Q000150:complications; D012871:Skin Diseases / Q000139:chemically induced*; D014860:Warts / Q000139:chemically induced*
D007166:Immunosuppressive Agents; D016572:Cyclosporine